Natuzzi SpA (NYSE:NTZ) shares decreased -0.55% in last trading session and ended the day at $1.81. NTZ Gross Margin is 28.00% and its has a return on assets of -12.80%. Natuzzi SpA (NYSE:NTZ) quarterly performance is -18.10%.
Natuzzi S.p.A. (Natuzzi) is primarily engaged in the design, manufacture and marketing of contemporary and traditional leather and fabric-upholstered furniture, principally sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, and living room accessories. It sells its Natuzzi furniture principally through franchised Divani & Divani by Natuzzi and Natuzzi furniture stores. As of March 31, 2010, Natuzzi sells its furniture in various locations, which include 124 Divani & Divani by Natuzzi and 174 Natuzzi stores, of which 56 are directly owned by the Company; eight outlets, and 17 concessions in the United Kingdom and Republic of Ireland.
Carlisle Companies Incorporated (NYSE:CSL) ended the last trading day at $99.79. Company weekly volatility is calculated as 1.75% and price to cash ratio as 28.40. Carlisle Companies Incorporated (NYSE:CSL) showed a weekly performance of 2.11%.
Carlisle Companies Incorporated (Carlisle) is a holding company for Carlisle Corporation and its wholly-owned subsidiaries. Carlisle is a diversified manufacturing company. The Company operates through four segments.. The Carlisle Construction Materials segment manufactures and sells rubber, thermoplastic polyolefin and polyvinyl chloride membrane roofing systems. The Carlisle Interconnect Technologies segment designs and manufactures wire, cable, connectors, contacts, and cable assemblies for the transfer of power and data for the aerospace, medical, defense electronics, test and measurement equipment.
David A. Roberts, Chairman and CEO of Carlisle Companies Incorporated (NYSE:CSL), will be presenting at the RBC Capital Markets’ Global Industrials Conference at the Mandarin Oriental Hotel in Las Vegas, NV at 8:35 a.m. (Pacific Time) on Thursday, September 10, 2015.
On 09 September, Allegion plc Ordinary Shares (NYSE:ALLE) shares decreased -0.27% and was closed at $60.20. Allegion plc Ordinary Shares (NYSE:ALLE) year to date (YTD) performance is 8.91%.
Allegion plc is a provider of security products and solutions. The Company offers a portfolio of mechanical and electronic security products across a range of brands. Its products include door closers and controls, electronic security products, exit devices, time, attendance and workforce productivity systems, door and door frames (steel), electronic and biometric access control systems, locks, locksets and key systems, video analytics systems and other accessories.
Allegion, plc (NYSE:ALLE), a leading global security products and solutions provider, announced that its board of directors declared a quarterly dividend of $0.10 per ordinary share of the company. The dividend is payable on Sept. 30, 2015, to shareholders of record on Sept. 16, 2015.
Nuverra Environmental Solutions, Inc. (NYSE:NES) shares decreased -11.52% in last trading session and ended the day at $2.38. NES Gross Margin is 27.40% and its has a return on assets of -56.00%. Nuverra Environmental Solutions, Inc. (NYSE:NES) quarterly performance is -56.88%.
Nuverra Environmental Solutions, Inc. (Nuverra) provides full-cycle environmental solutions to customers focused on the development and ongoing production of oil and natural gas from shale formations. Nuverra provides one-stop, total environmental solutions, including delivery, collection, treatment, recycling, and disposal of water, wastewater, waste fluids, hydrocarbons, and restricted solids that are part of the drilling, completion, and ongoing production of shale oil and natural gas.
Nuverra Environmental Solutions (NYSE:NES) had its price target cut by Imperial Capital from $5.00 to $2.50in a research report published onWednesday, MarketBeat Ratings reports. They currently have a line rating on the stock.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) caters to the Healthcare space. Its weekly performance is 52.07%. On the last day of trading company shares ended up $11.36. Akebia Therapeutics, Inc. (NASDAQ:AKBA) distance from 50-day simple moving average (SMA50) is 30.01%.
Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease. The Company’s lead product candidate, AKB-6548, is being developed as a once-daily, oral therapy.
Akebia Therapeutics, Inc. (NASDAQ: AKBA) announced positive top-line results from its Phase 2 study of vadadustat (formerly AKB-6548) in dialysis patients with anemia related to chronic kidney disease (CKD). The study achieved its primary objective, indicating that vadadustat maintained stable hemoglobin (HGB) levels throughout the 16-week treatment period following conversion from recombinant erythropoiesis-stimulating agent (rESA) therapy. Vadadustat demonstrated a favorable safety profile with no drug-related serious adverse events and no deaths.
Leave a Reply